Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bright Minds Biosciences Inc

29.25
-2.7900-8.71%
Volume:28.70K
Turnover:865.29K
Market Cap:206.04M
PE:-192.72
High:31.84
Open:30.61
Low:29.24
Close:32.04
Loading ...

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

GlobeNewswire
·
06 Mar

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

GlobeNewswire
·
04 Mar

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

GlobeNewswire
·
24 Feb

Piper Sandler Initiates Bright Minds Biosciences at Overweight

MT Newswires Live
·
23 Jan

Yasmeen Rahimi’s Buy Rating on Bright Minds Biosciences Driven by Promising Potential of BMB-101 for Epilepsy Treatment

TIPRANKS
·
23 Jan

Bright Minds Biosciences initiated with an Overweight at Piper Sandler

TIPRANKS
·
23 Jan

Cantor Fitzgerald Initiates Bright Minds Biosciences With Overweight Rating

MT Newswires Live
·
10 Jan

HC Wainwright Initiates Bright Minds Biosciences With Buy Rating, $85 Price Target

MT Newswires Live
·
10 Jan

Bright Minds Biosciences initiated with a Buy at H.C. Wainwright

TIPRANKS
·
10 Jan

Press Release: Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Dow Jones
·
07 Jan

Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase

TIPRANKS
·
31 Dec 2024

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

PR Newswire
·
09 Dec 2024

Baird Initiates Bright Minds Biosciences at Outperform

MT Newswires Live
·
26 Nov 2024

Bright Minds Biosciences Inc : Baird Initiates Coverage With Outperform Rating and $75 Target Price

THOMSON REUTERS
·
26 Nov 2024

Bright Minds Biosciences: Promising Pipeline and Strategic Positioning Justify Buy Rating

TIPRANKS
·
26 Nov 2024

Bright Minds Biosciences initiated with an Outperform at Baird

TIPRANKS
·
26 Nov 2024